- Home
- Publications
- Publication Search
- Publication Details
Title
Robo4 vaccines induce antibodies that retard tumor growth
Authors
Keywords
Immunotherapy, Conjugate vaccines, ADCC, Cancer
Journal
ANGIOGENESIS
Volume 18, Issue 1, Pages 83-95
Publisher
Springer Nature
Online
2014-10-27
DOI
10.1007/s10456-014-9448-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody
- (2013) M. Yoshikawa et al. BLOOD
- IgG4 subclass antibodies impair antitumor immunity in melanoma
- (2013) Panagiotis Karagiannis et al. JOURNAL OF CLINICAL INVESTIGATION
- Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents
- (2012) M Jarosz et al. GENE THERAPY
- Shear stress, tip cells and regulators of endothelial migration
- (2011) Xiaodong Zhuang et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- High-affinity memory B cells induced by conjugate vaccines against weak tumor antigens are vulnerable to nonconjugated antigen
- (2011) N. Savelyeva et al. BLOOD
- Robo4 Maintains Vessel Integrity and Inhibits Angiogenesis by Interacting with UNC5B
- (2011) Alexander W. Koch et al. DEVELOPMENTAL CELL
- Identification and angiogenic role of the novel tumor endothelial marker CLEC14A
- (2011) M Mura et al. ONCOGENE
- The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B—a prerequisite for clinical development
- (2011) Elisabeth J.M. Huijbers et al. VACCINE
- FcγRIIB, FcγRIIIB, and systemic lupus erythematosus
- (2010) Heather A. Niederer et al. Annals of the New York Academy of Sciences
- The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
- (2010) Dietmar W. Siemann CANCER TREATMENT REVIEWS
- MR angiogenesis imaging with Robo4- vs. αVβ3-targeted nanoparticles in a B16/F10 mouse melanoma model
- (2010) Kent S. Boles et al. FASEB JOURNAL
- Vaccination against the extra domain-B of fibronectin as a novel tumor therapy
- (2010) Elisabeth J. M. Huijbers et al. FASEB JOURNAL
- Impact of bevacizumab chemotherapy on craniotomy wound healing
- (2010) Aaron J. Clark et al. JOURNAL OF NEUROSURGERY
- Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma
- (2010) B K Haller et al. ONCOGENE
- Vascular Robo4 restricts proangiogenic VEGF signaling in breast
- (2010) R. Marlow et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of potent biodegradable adjuvants that efficiently break self-tolerance—A key issue in the development of therapeutic vaccines
- (2009) Maria Ringvall et al. VACCINE
- A GABP-binding element in the Robo4 promoter is necessary for endothelial expression in vivo
- (2008) Y. Okada et al. BLOOD
- Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated via WASP and other actin nucleation-promoting factors
- (2008) Helen Sheldon et al. FASEB JOURNAL
- Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability
- (2008) Christopher A Jones et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now